Drop your drugs. We'll show the spread.
Built for the PBM renewal conversation. Paste your top drugs, your full formulary, or your top-25 by spend — we cross-reference against CMS NADAC, FDA Orange Book ANDA filings, Part D formulary tier placement across 329 plans, and CMS Part D claim-level utilization, then rank by gross savings opportunity before rebates.
Paste the drugs you actually spend money on.
One drug per line. Generic name, brand name, or NDC — we match all three. Combination products are best entered as the brand name. The pre-filled list is a top-spend Part D sample to demo the tool; replace with yours.
Three numbers shape the answer.
Covered lives scales the opportunity to your book. Minimum spend filters out molecules too small to move. Minimum generic manufacturer count filters out drugs where competitive pricing doesn't yet exist.
Where the money actually is.
Ranked by gross annualized opportunity per your covered-life count. "Opportunity" is the dollar delta between average current NADAC and lowest available NADAC across the molecule's NDCs, scaled by Part D claim volume. Numbers are pre-rebate — see Q&A below on how to net.
What this report does and doesn't tell you.
Is the NADAC floor what my PBM actually charges me?
No. NADAC is the average price retail pharmacies pay wholesalers — published weekly by CMS. It is not what your PBM bills your plan. Your PBM cost is set by your contract: typically AWP-X% with a MAC list overlay on generics, plus dispensing fees.
The gap between NADAC and what your PBM bills you is called spread. On legacy contracts with MAC pricing on generics, that spread commonly runs 100–400% on high-volume molecules. The leak report quantifies the molecule-by-molecule exposure; an actual NADAC pass-through contract is how you collect it.
Does this account for rebates I'd lose by switching off brand?
No — the opportunity column is gross of rebates. When you move a brand molecule to a lower tier or push toward generics, you lose the brand rebate flow that offset gross spend.
Year-1 typical realization: 30–60% of gross opportunity. Year-2: approaches gross as utilization fully migrates. Single-source brands with rebate guarantees in your PBM contract will resist tier moves the hardest. Molecules with 10+ generic manufacturers usually carry minimal rebate exposure — those are the cleanest wins.
How do I use this in my next PBM renewal RFP?
Three specific moves the leak report enables:
1. Demand NADAC pass-through on the top 10 leaks. Bring the molecule list to RFP. Ask incumbent and challenger PBMs to commit to NADAC+dispensing-fee pricing on these specific NDCs.
2. Require tier-move authority on generic-rich molecules. For drugs with 10+ ANDAs, ask for contractual right to move tiers mid-year, not just at plan-year reset.
3. Demand quarterly transparency reports per molecule. Net cost, rebate flow, spread — per drug, per quarter.